Unlocking gene delivery to the brain with Dyno bCap 1^TM Technology

PROBLEM

Delivering genes to the brain has been an elusive goal due to the blood-brain barrier

SOLUTION

Dyno bCap 1 Technology unlocks the transformative potential of gene therapies pan-brain and throughout the CNS

With Dyno bCap 1 Technology, gene therapies can now cross the blood brain barrier after intravenous administration

100x pan-brain transduction relative to natural capsid serotypes such as AAV9
10x liver detargeting relative to delivery with AAV9
1x production efficiency compared to AAV9

Reaching 5-20% of neurons and broader cell types across the CNS at a low dose of 1e13 vg/kg in NHPs

Delivery to the spinal cord and across the CNS

Off-target transduction of Dorsal Root Ganglion similar to AAV9

Expanding the promise of gene therapy with Generative Artificial Intelligence

Designed with Precision

7 Wonders: Unlocking the CNS with 7 Sequence Changes

The Dyno bCap 1 capsid differs from the natural AAV9 capsid in 7 locations spread across 23 positions of the sequence
2.8*10²⁵ ways to randomly make 7 sequence changes to an AAV capsid
Dyno’s AI led the way

Dyno bCap 1 technology: One differentiated CNS delivery solution

Enabling CNS gene delivery optimized across multiple properties: 100x CNS transduction, 10x liver detargeting and 1x AAV production
Cross-species translation: enhanced transduction crossing the blood brain barrier in both cynomolgus monkey (Macaca fascicularis) and African green monkey (Chlorocebus sabaeus)
Patents pending

Dyno bCap 1 technology and other Dyno proprietary CNS capsids are available to license for select payloads and indications

Inquire: bd@dynotx.com
Learn more about Dyno’s AI-powered sequence design platform
Keep me updated about Dyno bCap 1 technology and new announcements on Dyno eCap^TM, Dyno hCap^TM and Dyno mCap^TM technologies for delivery of gene therapies to eye, heart and muscle